What question did this study set out to answer?

This research aims to optimize oxaliplatin-loaded solid lipid nanoparticles (SLNs) to improve their therapeutic efficacy against colorectal cancer.

January 25, 2026

View Full Paper

Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer

SKSamanwita KhanraJSS Academy of Higher Education and Research PRParikshit RoychowdhuryJSS Academy of Higher Education and Research NBNihar Ranjan BhuyanHimalayan University

Key Points

This research aims to optimize oxaliplatin-loaded solid lipid nanoparticles (SLNs) to improve their therapeutic efficacy against colorectal cancer.
Prepared SLNs using a micro-emulsion technique and optimized via Box-Behnken Design.
Characterized nanoparticles by evaluating drug release, loading, encapsulation efficiency, and stability.
Conducted cytotoxicity assays on HT-29 colorectal cancer cell line using Sulforhodamine B assay.
Optimized SLNs had a mean particle size of 115.41 nm and zeta potential of +23.1 mV, indicating stability.
Drug loading was 10.2% and encapsulation efficiency was 92%.
In vitro release studies showed sustained drug release reaching 97% over 48 hours.
Cytotoxicity assays revealed enhanced efficacy of SLNs with IC₅₀ of 0.9751 μg/mL at 24 h, significantly lower than free oxaliplatin.

Abstract

Introduction: Oxaliplatin is a third-generation platinum-based chemotherapeutic agent widely used for colorectal cancer treatment. However, its therapeutic application is lim-ited by low solubility, systemic toxicity, and poor bioavailability. Methods: Solid lipid nanoparticles (SLNs) were prepared using a micro-emulsion technique and further optimized via Box-Behnken Design (BBD), considering key formulation variables including Glyceryl Monostearate, Soya Lecithin, and Tween 80. Nanoparticles were charac-terized by in vitro drug release, drug loading, encapsulation efficiency, zeta potential, particle size, and polydispersity index (PDI). Cytotoxic efficacy against the HT-29 colorectal cancer cell line was evaluated using the Sulforhodamine B (SRB) assay. Results: The optimized SLN formulation exhibited a mean particle size of 115.41 nm, PDI of 0.202, and zeta potential of +23.1 mV, indicating stability and efficient cellular uptake. Drug loading and encapsulation efficiency were 10.2 ± 0.4% and 92 ± 3.2%, respectively. In vitro release studies showed sustained drug release, reaching 97% over 48 hours. Cytotoxicity as-says demonstrated enhanced efficacy of Oxaliplatin SLNs, with IC₅₀ values of 0.9751 μg/mL at 24 h and 1.168 μg/mL at 48 h, compared to free Oxaliplatin (52.95 μg/mL at 24 h and 16.33 μg/mL at 48 h). Discussion: GMS-based SLNs optimized with Tween 80, lecithin, and DDAB exhibited ideal size, charge, and high encapsulation. FTIR and DSC analyses confirmed component compat-ibility. The formulation showed sustained release and enhanced cytotoxicity, highlighting its potential to improve Oxaliplatin delivery and therapeutic efficacy in colorectal cancer. Conclusion: The optimized Oxaliplatin SLNs demonstrated improved solubility, controlled release, and enhanced cytotoxicity, confirming their promise as a nanocarrier system for col-orectal cancer therapy. Further in vivo studies are required to validate clinical effectiveness.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Khanra et al. (Mon,) studied this question.

synapsesocial.com/papers/6975b38dfeba4585c2d6f066 https://doi.org/https://doi.org/10.2174/0115680096414252251125053406

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI에게 질문

Bookmark

View Full Paper